Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.54 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24633854 | 0.94 | MDM2 (0.51) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL22444699 | 0.94 | MDM2 (0.51) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL31369983 | 0.94 | MDM2 (0.51) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29855552 | 0.94 | MDM2 (0.51) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL22444774 | 0.89 | MDM2 (0.51) | MDM2MDM4TP53CASP3SLC17A5 | |
| SCHEMBL27417735 | 0.88 | MDM2 (0.48) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL31634977 | 0.88 | MDM2 (0.48) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL22444786 | 0.86 | MDM2 (0.44) | MDM2MDM4TP53CASP3 | |
| SCHEMBL22444938 | 0.85 | HDAC1 (0.48) | MDM2MDM4TP53 | |
| SCHEMBL430008 | 0.85 | MDM2 (0.56) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | MDM2 164/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.